Mechanism of Action
D-Amino Acid-Enhanced Protease Resistance
Maximin peptides naturally contain D-amino acids at specific positions that are enzymatically introduced by peptidyl-amino acid alpha-hydroxylating enzyme and racemase activity post-translationally. These D-residues create protease-resistant kinks in the peptide backbone that natural L-amino acid-specific proteases cannot cleave efficiently. This natural incorporation of D-amino acids provides a template for synthesizing protease-stable AMP analogs as drug candidates.
Opioid Receptor Activity (Maximin H Series)
The maximin H (hallucinogenic) subfamily, particularly maximin H5, contains the opioid-active sequence Tyr-Pro at the N-terminus. These peptides bind mu and delta opioid receptors and produce analgesia in animal models. The spatial arrangement of key pharmacophore residues is altered by the D-amino acid content, creating a novel opioid scaffold with potential for reduced tolerance development compared to classical L-peptide opioids.
Research Summary
Antimicrobial Activity of Maximin 1-4
PreclinicalMaximin 1-4 exhibit broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi. MIC values range from 1-20 uM. Unlike fully L-configured analogs, the D-amino acid variants show significantly enhanced stability in serum and tissue homogenates. The combined selectivity and stability profile makes maximins attractive leads for topical and wound-care antimicrobial applications.
Neuroactive Properties
PreclinicalMaximin H5 and related peptides have been studied as novel opioid peptides with analgesic activity in mouse hot-plate and tail-flick assays. The D-amino acid content alters receptor binding kinetics and potentially reduces mu-opioid receptor desensitization compared to morphine. These properties have motivated interest in maximins as templates for non-addictive analgesic development, though significant preclinical optimization is needed.
Calculate your Maximin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antimicrobial (in vitro) | 1-20 uM MIC | Single exposure | Direct application |
| Analgesia (animal) | 10-50 nmol/kg | Single injection | IV / ICV (research) |
No human protocols. D-amino acid stability advantage is significant for in vivo studies.
Interactions
Safety Profile
D-amino acid content provides unusual protease resistance compared to standard AMPs. Hemolytic activity varies by family member. The opioid-active H series raises addiction/dependence concerns for systemic use. No human clinical data for any maximin family member.
References
- [1]Chen T, et al. (2005). Bombesin-like peptides and neuropeptide Y from the skin of the Chinese red-bellied toad Bombina maxima. Peptides, 26(1), 88-93.
- [2]Lai R, et al. (2002). Characterization of antimicrobial peptides from skin secretions of the Chinese giant salamander. Biochem Biophys Res Commun, 295(4), 891-894.